<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Four patients with long QT type 2, aged 11 to 18 years from unrelated families, with recurrent <z:hpo ids='HP_0001279'>syncope</z:hpo> and polymorhic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> were studied </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001657'>Long QT syndrome</z:hpo> was diagnosed in these children at ages 4 to 7 years </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001279'>Syncope</z:hpo>, QT prolongation on electrocardiogram (corrected QT interval ≥ 490 milliseconds), notched T-wave <z:mp ids='MP_0000002'>morphology</z:mp>, <z:hpo ids='HP_0001662'>bradycardia</z:hpo>, and polymorphic <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> were found in <z:hpo ids='HP_0000001'>all</z:hpo> of the patients </plain></SENT>
<SENT sid="3" pm="."><plain>The KCNH2-L586M; KCNH2-G604S, KCNH2-L1045F; and a combined mutation KCNH2 T613M + SCN5A R190G were genotyped </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001279'>Syncope</z:hpo>, implantable cardioverter-defibrillator shocks, and <z:hpo ids='HP_0001649'>tachycardia</z:hpo> persisted in these patients, although they were receiving a full dose of β-blocker therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Adding a <z:chebi fb="199" ids="26708">sodium</z:chebi>-channel blocker (IC class) led to a reduction in the polymorphic <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>No <z:hpo ids='HP_0001279'>syncope</z:hpo> episodes were registered during the patients' 8 to 60 months of follow-up on the combined antiarrhythmic therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Further studies are needed to better define the possible role of <z:chebi fb="199" ids="26708">sodium</z:chebi>-channel blockers in patients with long QT type 2 </plain></SENT>
</text></document>